ANGLE appoints Dr. Joe Eid to its Board as Non-Executive Director

– UK, Guildford –  ANGLE plc (LON: AGL | OTC: ANPCY), a world-leading liquid biopsy company, today announced the appointment of Dr. Joe Eid (M.D.) to its Board as a Non-Executive Director effective from 19 January 2023.

“We are delighted that Joe has agreed to join the ANGLE Board. Joe brings valuable knowledge and experience in oncology drug development and the use of biomarkers in the clinical trials process and as companion diagnostics. This is a key focus for the Company’s pharma services business and will be of enormous benefit going forward.” said Board Chairman, Garth Selvey.

About Dr. Joseph Eid

Joe Eid is a qualified physician, board certified in medical oncology, hematology, and internal medicine. He is a highly experienced pharmaceutical industry executive with over 25 years of proven expertise in people and portfolio management, planning, designing, and executing Phase I to IV clinical trials, and building and managing clinical and medical affairs teams and strategies. He has successfully designed and implemented clinical development, medical affairs, and life cycle management plans for pharmaceutical products including cytotoxic agents, monoclonal antibodies, immuno-oncology agents, antibody-drug conjugates, and CAR-T Cell therapies.

Joe Eid most recently served as CMO and Head of Global Drug Development for Princeton, New Jersey-based Luzsana Biotechnology. His previous experience includes senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck & Co., and Hoffman-La Roche.

Whilst at Merck, he led the global Keytruda first-in-human strategy, including oversight of the clinical, regulatory, and manufacturing planning and execution and development of the PD-L1 biomarker strategy on tissue biopsy, which led to a first-in-class anti-PD-1 BLA filing and approval in the US.

Dr. Joe Eid said: “I believe that ANGLE’s Parsortix technology and unique liquid biopsy approach has enormous potential both in oncology drug development and in the clinical setting. I look forward to leveraging my extensive experience of the development and use of biomarkers in oncology to drive forward the Company’s strategy and to use my network of pharma industry, clinical and academic thought leaders to accelerate the Company’s commercial development.”

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with sample-to-answer solutions. ANGLE’s proven patent-protected circulating tumor cell harvesting technology is known as the Parsortix system.

ANGLE’s Parsortix system is FDA-cleared for its intended use in metastatic breast cancer and is currently the first and only FDA-cleared medical device to harvest intact circulating cancer cells from the blood.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.